Key Segmentation
By Product
-
Mvasi
-
Zirabev
-
Aybintio
-
Onbevzi
-
Vegzelma
-
Others
By Application
-
Colorectal Cancer
-
Non-Small Cell Lung Cancer
-
Renal Cell Carcinoma
-
Glioblastoma
-
Cervical Cancer
-
Ovarian Cancer
-
Others
By Distribution Channel
-
Hospital Pharmacies
-
Retail Pharmacies
-
Online Pharmacies
By End User
-
Hospitals & Oncology Clinics
-
Specialty Care Centers
-
Ambulatory Surgical Centers
-
Others
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
The major growth factor is the rising global incidence of cancer, combined with healthcare system cost-containment imperatives and patent expiration of reference bevacizumab (Avastin).
The bevacizumab biosimilars market was valued at USD 2.18 billion in 2025.